Kymera Therapeutics (KYMR) Stock: Buy, Sell, or Hold?
KYMR - Kymera Therapeutics, Inc. Common Stock
$107.39
-2.73 (-2.48%)
▼
5d:
-4.07%
30d:
-9.47%
90d:
-6.42%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 03, 2026
30d
Get Alerted When KYMR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KYMR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: KYMR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: KYMR is currently trading at $107.39, which is considered oversold relative to its 30-day fair value range of $112.38 to $120.85.
Technical Outlook: Technically, KYMR is in a strong uptrend. The price is currently testing key support at $106.53. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KYMR scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $138.64 (+29.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KYMR is in a strong uptrend. The price is currently testing key support at $106.53. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KYMR scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $138.64 (+29.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$112.38 -
$120.85
Company Quality Score
55/100
(HOLD)
Options IV Signal
33th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
Protect Your Profits
Holding KYMR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 33th percentile)
- BEARISH: Weak technical setup (34/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 29.1% below Wall St target ($138.64)
Trading Range Analysis
30-Day Trading Range
$112.38 -
$120.85
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$11.92
(11.1%)
Support & Resistance Levels
Support Level
$106.53
Resistance Level
$123.00
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.06
Wall Street Target
$138.64
(+29.1%)
Revenue Growth (YoY)
466.4%
Profit Margin
-285.3%
Share & Embed Analysis
Last updated: October 02, 2026 8:27 PM ET
Data refreshes hourly during market hours. Next update: 9:27 PM
Data refreshes hourly during market hours. Next update: 9:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYMR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Bruce Booth
SELL
5900 shares
2026-04-22
Jeremy G Chadwick
SELL
300 shares
2026-04-22
Bruce Booth
SELL
100 shares
2026-04-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
Advanced KYMR Option Strategies
Professional options setups generated by AI based on today's KYMR price and gamma walls.
